Date: 2013-11-05
Type of information: Capital increase
Company: Bionor Pharma (Norway)
Investors:
Amount: NOK 20.6 million (€ 2.26 million)
Funding type: capital increase
Planned used:
Others: * On November 5, 2013, Bionor Pharma announced that the share capital increase was registered in the Norwegian Register of Business Enterprises (Foretaksregisteret) 5 November 2013. The Company’s new share capital after registration is NOK 56,456,587comprising 225,826,348 shares with a par value of NOK 0.25. * On October 23, 2013, Bionor Pharma announced that its subsequent offering was oversubscribed. The subscription period ended on 22 October 2013 at 16.30 (CET). As a result of the Subsequent Offering, the Company will issue 7,500,000 Offer Shares at NOK 2.75 per share raising gross proceeds of approximately NOK 20.6 million (€ 2.26 million). Payment for the Offer Shares will fall due on 28 October 2013 and delivery will take place on or about 8 November 2013. Following registration of the issue of the Offer Shares the total number of issued shares in the Company will increase by 7,500,000 shares, from 218,326,348 shares to 225,826,348 shares. The new share capital after the registration of the share capital increase will be NOK 56,456,587. The Offer Shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the Subsequent Offering has been registered with the Norwegian Register of Business Enterprises. It is expected that the share capital increase will be registered in the Norwegian Register of Business Enterprises on or about 7 November 2013 and that the Offer Shares will be admitted to trading on Oslo Børs 8 November 2013. SEB is acting as sole manager for the Subsequent Offering. * On October 7, 2013, Bionor Pharma announced that, at the extraordinary general meeting held on 7 October 2013, the Board of Directors was granted an authorization to increase the share capital by up to NOK 1,875,000 for the purpose of completing an offering with allocation preference to shareholders who were not allocated shares in the private placement completed on 12 September 2013. The Subsequent Offering will be directed towards existing shareholders as of 12 September 2013, as registered in the VPS on 17 September 2013, who were not allocated shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, would require any filing, registration or similar action, (the \"Eligible Shareholders\"). Eligible Shareholders have been granted 1 non-transferable Allocation Rights for each 15.628227 existing shares registered as of the Record Date rounded down to the nearest whole subscription right. The Allocation Rights, subject to applicable laws, provide rights to subscribe for and be allocated Offer Shares in the Offering. Over-subscription and subscription without Allocation Rights will be permitted. Allocation rights not used to subscribe for Offer Shares before the end of the subscription period will lapse without compensation to the holder, and consequently be of no value. The subscription period for the Subsequent Offering commences 8 October 2013 and expires at 16:30 hours (CET) on 22 October 2013. The subscription price per Offer Share is NOK 2.75, equal to the subscription price in the Private Placement. The number of allocation rights can be viewed on the shareholders’ VPS accounts on or about 8 October 2013. The subscription rights can be exercised by duly completing and delivering the subscription form, in accordance with the terms and conditions set out in the Prospectus, to the following subscription office:
Therapeutic area: Infectious diseases
